Skip to main content
Premium Trial:

Request an Annual Quote

Natera, ProPath Team Up for Distribution of Panorama NIPT

NEW YORK (GenomeWeb News) – Natera today announced a US distribution deal with pathology services provider ProPath for Natera's Panorama non-invasive prenatal screening test.

The test uses a blood draw to detect trisomy 21, 18, and 13, as well as monosomy X, triploidy, and sex chromosome aneuploidies. It employs Natera's algorithm called Next Generation Aneuploidy Testing Using SNPs to analyze cell-free DNA from both the mother and the fetus.

Natera also has deals with Quest Diagnostics, Bio-Reference Laboratories, and Arup Laboratories to offer Panorama in the US. In December, New York issued a permit for Natera's CLIA laboratory, allowing the company to offer its preconception and prenatal tests, including Panorama, to expecting parents in the state.

Financial and other terms of the ProPath deal were not disclosed.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.